30 closest matches · ranked by relevance
Multiple Myeloma
Primary: Percentage of Patients With MRD(-) Remissions at the Completion of Consolidation Therapy — 81.4 percentage of patients achieving MRD (-)
Multiple Myeloma · Myeloma · Disability Physical
Primary: Intervention Attendance (Feasibility) — 50 percentage of participants
Multiple Myeloma
Primary: Number of Participants Achieving a Complete Response — 51 Participants
Multiple Myeloma · Smoldering Multiple Myeloma · Monoclonal Gammopathy of Undetermined Significance
Primary: Count of Participants With Positive and Negative 18F-FDG PET CT and F18-NaF PET CT Imaging Results in Individuals With MGUS, SMM, and MM. — 0; 1; 5; 10 Participants
Multiple Myeloma
Primary: Immune Response — 7 Particpants
Myeloma-Multiple · Myeloma, Plasma-Cell
Primary: Number of Participants That Had Any Grade ≤2, and 3, 4 and 5 Adverse Events Following Administration of T Cells Expressing Anti- Signaling Lymphocytic Activation…
Multiple Myeloma
Primary: Phase I: Number of Patients With Dose Limiting Toxicity — 0; 0; 0; 0 Participants
Multiple Myeloma · Auto Stem Cell Transplant
Primary: To Determine the Progression-free Survival of Patients With Multiple Myeloma Treated With Tandem Cycles of High-dose Melphalan Followed by High-dose Melphalan in…
Multiple Myeloma
Primary: Percentage of Patients With an Objective Response — 31 percentage of patients
Multiple Myeloma
Primary: Percentage of Participants With 1-year Response Rate of CR/sCR — 52.9; 50.0 percentage of participants — p=0.3657
Multiple Myeloma · Plasma Cell Myeloma
Primary: Overall Survival — 68 Months
Refractory Multiple Myeloma · Smoldering Multiple Myeloma · Stage I Multiple Myeloma
Primary: Maximum Tolerated Dose (MTD) — 1600 cGy
Multiple Myeloma
Primary: Number of Multiple Myeloma (MM) Participants Categorized by Clinical Characteristics — 342; 366; 48; 36 Participants
Multiple Myeloma
Primary: Feasibility of Obtaining Baseline Clinical and PRO Data Capture From 200 Consented Patients. — 196 Participants
Multiple Myeloma
Primary: Maximum Tolerated Dose (MTD) — 20 mg LBH589
Refractory Multiple Myeloma · Stage I Multiple Myeloma · Stage II Multiple Myeloma
Primary: Overall Survival — 9 Participants
Multiple Myeloma, Relapsed · Multiple Myeloma, Refractory to Standard Treatment
Primary: Maximum Tolerated Dose (MTD) of Gy — NA Participants
Multiple Myeloma and Plasma Cell Neoplasm
Primary: Event-free Survival — 29 percentage of participants
Multiple Myeloma
Primary: Response Rates by Blade Criteria — 2; 5; 3; 2 Participants
Multiple Myeloma
Primary: Number of Participants With Pulmonary Toxicity — 32 Participants
Refractory Multiple Myeloma · Stage II Multiple Myeloma · Stage III Multiple Myeloma
Primary: CR and Near CR Rates — 39; 22 percentage of participants
Refractory Multiple Myeloma · Stage I Multiple Myeloma · Stage II Multiple Myeloma
Primary: The Number of Confirmed Responses (Complete Response [CR], Very Good Partial Response [VGPR], or Partial Response [PR]) — 0 participants
Extramedullary Plasmacytoma · Isolated Plasmacytoma of Bone · Light Chain Deposition Disease
Primary: Median Progression Free Survival (mPFS) — 76.4 months
Multiple Myeloma
Primary: Number of Patients Able to Collect >=6 x 106 CD34+ Cells/kg in <= 2 Collections. — 11; 0; 14 Participants — p=0.90
Multiple Myeloma
Primary: Percentage of Participants With Minimal Residual Disease (MRD)Negative Complete Response (CR) Per International Myeloma Working Group (IMWG) Criteria — 70.4 percentage…
Multiple Myeloma and Plasma Cell Neoplasm
Primary: Patients With Overall Confirmed Response — 3; 5; 10 participants
Multiple Myeloma and Plasma Cell Neoplasm
Primary: The Number of Confirmed Hematologic Responses (Complete, Partial, or Very Good Partial Response) — 39; 11; 9; 10 participants
Multiple Myeloma
Primary: Number of Participants With Adverse Events (AEs) — 6 Participants
Multiple Myeloma · Amyloidosis
Primary: Number of Participants Without Renal Allograft Rejection at 6 Months Post-transplant — 1 Participants
Multiple Myeloma
Primary: The Number of Participants With a Significant Increase in Serum Creatinine at 12 Months — 17; 13 Participants